Category: Press Releases

Nexen Tire N’FERA SPORT Golf and Leon approved by VW and Leon

SEOUL, South Korea, June 15, 2021 (GLOBE NEWSWIRE) — Nexen Tire, a leading global tire manufacturer, today announced that the N’FERA SPORT will feature as original equipment on Volkswagen’s eighth generation Golf and SEAT’s fourth generation Leon, fitted in size 225/45R17 91W.

The Golf, also known as the “Hot Hatch,” is Volkswagen’s flagship model and has sold over 35 million units since its launch in 1979. Meanwhile, the Leon is a representative hatchback model of Spanish automotive company SEAT, with over 2 million units sold since launching in 1999.

The N’FERA SPORT is designed for European sports vehicles, providing outstanding performance and safety during high-speed driving. In particular, this product is characterized by excellent handling and braking performance, even during sudden stops.

The tire has received a tally of accolades of strong ratings and results, including from top German automotive magazine Auto Club Europa (ACE) Lenkrad which recently rated the N’FERA SPORT in first place in the summer tire test.

Meanwhile, Nexen Tire is continuing to increase its OE supply across all countries in Europe.

About Nexen Tire

Nexen Tire, established in 1942, is a global tire manufacturer headquartered in South Korea. Nexen Tire, one of the world’s fastest growing tire manufacturers, currently interacts with approximately 150 countries around the world and owns four manufacturing plants – two in Korea (Yangsan and Changnyeong) and one in Qingdao, China. Another plant in Žatec, the Czech Republic has also begun operation in 2019. Nexen Tire produces tires for passenger cars, SUVs, and light trucks with advanced technology and excellence in design. Nexen Tire supplies OE tires to global car makers in various countries around the world. In 2014, the company achieved a grand slam of the world’s top 4 design awards for the first time amongst the various tire makers in the world.

For more information, please visit https://www.nexentire.com/international/

CONTACT: Sylvia Chang, sylvia.chang@pivotp.co.kr

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f20b5d8-f6e9-49c0-a657-09865c6b3295

VistaJet Business

New report measures value of business travel for first time

London, June 15, 2021: Only 24 months ago, business travel was synonymous with global corporations and senior executives’ roles. During the global lockdowns, companies have experienced the direct impact of no travel or in-person meetings on their business functions and operations. In new research from VistaJet, the first and only global business aviation company, in association with WSJ Intelligence, that impact is quantified for the first time.

For The Future of Business Travel report over 200 high-level company executives in the U.S., EMEA and APAC were surveyed about the essential role and value of travel in their professional lives.

During the pandemic, travel has been limited for 90% of companies surveyed, and almost all (97%) said their businesses experienced negative impact directly related to those restrictions. Nearly one-quarter (24%) indicated massive or substantial disruptions across all eight areas measured, and 87% cited massive or substantial disruption in at least one area. More than a third (37%) said international business development and product launches took a hit due to a lack of in-person presence.

As restrictions ease, built-up anticipation for business travel is clear, with 81% saying business travel will be more important than ever to driving success. Among respondents who take eight or more private flights a year, 60% plan to significantly increase in-person meetings.

VistaJet Global 7500

VistaJet has seen a surge of 49% in corporate interest around the world since the start of the pandemic, confirming that flying private continues to be a key support for business travel. The main benefits of taking private flights for business travel are reported by those surveyed, in order, as flexibility, efficiency, safety and privacy. The two top priorities for trips are visiting partners and vendors and going to industry events, each at 34%. Managing current relationships and building new ones are also key drivers.

The return to business travel largely hangs on regulations — 46% of respondents are waiting for destinations to reopen; 42% want updated COVID-19 data and rules for destinations; 36% seek support in case COVID-19 regulations change during a trip; and the same number await relaxation of their own company’s travel policies.

Ian Moore, Chief Commercial Officer, VistaJet said: “The COVID-19 pandemic has upended the world, including travel. It also showed that some business travel is truly essential and having to forgo in-person trips came at a real cost to companies. Additionally, it is hard to read a room when everyone is in individual windows on screen — misunderstandings can occur, especially across cultures, and these in turn can become costly mistakes.”

To further support businesses around the world connect and restart the economy in the midst of heightened market insecurity, VistaJet recently launched a new Corporate Membership, offering speed and maximum flexibility with payment in arrears, unlimited flying hours, guaranteed availability of additional aircraft, and streamlined travel logistics.

For the full findings of The Future of Business Travel report, and to download a copy, please visit vistajet.com/businesstravel.

Information
Jennifer Farquhar | VistaJet | press@vistajet.com

About VistaJet
VistaJet is the first and only global business aviation company. On its fleet of over 70 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.
VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.
More VistaJet information and news at vistajet.com

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S. air carriers, including XOJET Aviation LLC.

Attachments

• VistaJet Business
• VistaJet Global 7500
• VistaJet Technology

PETALING JAYA, Malaysia, June 14, 2021 (GLOBE NEWSWIRE) — Toga Limited (OTC: TOGL) through its wholly owned subsidiary, TOGL Technology Sdn Bhd, collaborates with a renowned cloud computing company and an electronic Know-Your-Customer (e-KYC) technology provider to expediate the online process of identifying and verifying individuals from five days to 24 hours, for its social media mobile app, Yippi.

The strategic partnership enables the Yippi customer service (CS) team to reduce the turnaround time for the online process of identifying and verifying individuals anytime and anywhere, as the e-KYC system allows new users to open a Yippi account and verify their identities simply by scanning their national identity card and taking a photo.

“With the e-KYC system in place, we are able to reduce identity fraud by means of its comprehensive ID document security check; comprehensive artificial intelligence (AI) model specifically facial recognition, and risk engine that can identify frauds automatically, hence speeding up approval notifications for our CS team with the necessary information to approve or reject applications, as needed,” said TOGL Technology Chief Technology Officer, Mr. Freddy Chia Kah See.

“Additionally, under special circumstances, our team also conducts e-KYC to utilize technology like AI, machine learning and predictive algorithms to manage the process,” he added.

“The introduction of e-KYC is also in line with our efforts to facilitate greater digital offerings of Yippi services, and we expect it will pave the way to greater innovation in the social media app sector, including end-to-end offerings of digital services for our users,” said Mr. Chia.

Yippi applies an e-KYC digital and remote online solution system, which combines biometrics security technology, “spoof detection” and optical character recognition. Biometric security analyzes the unique characteristics of a person, such as one’s voice, iris or fingerprints. Spoof detection, also called “liveness”, entails a user responding to a challenge, such as blinking on cue, which is an action impossible for a static image a fraud might use. Optical character recognition transforms a picture of an ID card into text that can be compared against a database for name and identity verification.

Contact:

Alexander D. Henderson
TOGA LIMITED, 515 S. Flower Street, 18^th Floor, Los Angeles, CA 90071
(949) 333-1603
info@togalimited.com

Certain statements in this press release are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact (including, but not limited to, statements to the effect that Toga Limited or its management (the “Company”) “anticipates,” “plans,” “estimates,” “expects,” or “believes,” or the negative of these terms and other similar expressions) should be considered forward-looking statements, including, without limitation, statements regarding the Company’s guidance, outlook, growth, opportunities and long-term strategy. These statements involve certain risks and uncertainties that may cause actual results to differ materially from expectations as of the date of this release. These risks and uncertainties include, without limitation, risks associated with the impact of the COVID-19 pandemic; the Company’s ability to execute on its long-term strategy; the Company’s ability to successfully compete in its intensely competitive industry; the Company’s ability to manage its growth; the Company’s ability to maintain or improve its operating margins; the Company’s ability to identify and react to trends in consumer preferences; product supply disruptions; general economic conditions; accounting standard changes; and other factors as set forth from time to time in the Company’s Securities and Exchange Commission filings, including, without limitation, the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company intends these forward-looking statements to speak only as of the time of this Press Release and does not undertake to update or revise them as more information becomes available, except as required by law.

Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round

• Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fund
• Alentis is focused on the development of breakthrough treatments for fibrotic diseases and associated cancers

Paris, France, 15 June 2021 – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today announces that it has become a key investor as part of a $67 million Series B financing round in Alentis Therapeutics (Alentis). The Swiss biotech company, a spin-off of French Inserm with R&D in Strasbourg, France, is developing breakthrough therapies for patients suffering from fibrotic diseases and associated cancers.

Proceeds from the financing round will be used for proof-of-concept clinical trials of Alentis’ first-in-class assets, uniquely targeting fibrosis pathways for the treatment of life-threatening advanced liver and kidney fibrosis as well as associated cancers. Alentis expects to initiate its first clinical trial by the end of 2021.

Jeito’s investment aims to enable Alentis to accelerate the clinical pathway for various indications, with the potential to provide life-changing treatments to severely ill patients who have no other options. The investment will also give the Company the opportunity to expand its pipeline and explore further indications, including fibrotic associated cancers.

The financing round brings in Jeito Capital and Morningside Venture Investments alongside existing investors BioMed Partners, BB Pureos Bioventures, Bpifrance, High-Tech Gründerfonds and Schroders Capital. Following the fundraise, Rafaèle Tordjman, Founder and CEO of Jeito Capital, will join Alentis’ Board of Directors.

This is Jeito’s fifth investment since launching its fund in 2020. With more than €250 million under management, Jeito Capital is building a strong and diversified portfolio in biotech and biopharma companies based in Europe with global reach focused on the treatment of life-threatening diseases. Previous investments include French companies SparingVision and InnoSkel, respectively in the fields of ophthalmology and rare skeletal disorders, Dutch biotech Neogene Therapeutics in solid tumors, and recently Pulmocide in respiratory diseases, based in the UK.

Alentis is led by a highly experienced management team from the biotech and pharma industries. The Company’s science is based on more than 10 years of research by founder Thomas Baumert, a world class hepatology expert who currently serves as the head of Inserm’s Institute of Viral and Liver Diseases. Prof. Baumert’s research in Claudin-1 is unique and, until now, has not been explored as a potential treatment target for fibrotic diseases.

Rafaèle Tordjman, founder and CEO of Jeito, said: “Our investment in Alentis at this pivotal time of development will be crucial for its success and we are looking forward to working closely alongside their very experienced team. Our expertise lies in helping management teams from the science right through to commercialization of the product and here we will aim to accelerate Alentis’ efforts towards the initiation of the company’s first clinical trials. This represents our fifth investment in our diverse portfolio and strengthens our commitment to investing in European biotechs working towards the development of life–saving assets targeted at diseases with unmet need based on outstanding science.”

Dr. Roberto Iacone, Chief Executive Officer at Alentis Therapeutics, said: “We are delighted to have closed this financing round with new investors Jeito Capital and Morningside Venture Investments, two well respected and highly knowledgeable institutions within the healthcare space who will bring invaluable experience to the Board as we progress towards the initiation of our first clinical trials. Building on 20 years of work and positive preclinical data collected on ALE.F02, we are confident in the success of the upcoming trials as we work with both new and existing investors towards commercialization, providing a much needed safe and effective treatment to patients suffering from fibrotic diseases and hepatobiliary cancers.”

About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.

About Alentis Therapeutics
Alentis Therapeutics is a Swiss-based biotech that focuses on developing breakthrough treatments for fibrotic diseases. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

The company’s lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung. These represent very large and expanding markets with high unmet need. Furthermore, the company uses a patient-derived drug and target discovery platform to develop medicines for advanced fibrosis.

Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression.

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.

For more information, visit https://alentis.ch/

For more information please contact:

Jeito Capital Rafaèle Tordjman, Founder and CEO contact@jeito.life Consilium Strategic Communications Mary-Jane Elliott / Melissa Gardiner / Davide Salvi / Kris Lam Jeito@consilium-comms.com

Tel: + 33 (0) 6 35 36 35 00 Tel: +44 (0) 20 3709 5700

LeddarTech joins Tech.AD Europe as the Lead Sponsor and as both a presenter and exhibitor at this live event at the Titanic Chaussee Berlin, Germany, on July 1-2, 2021. Join LeddarTech either in person or digitally by registering today at autonomous-driving-berlin.com.

QUEBEC CITY, June 15, 2021 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in Level 1-5 ADAS and AD sensing technology, is excited to be reigniting its physical event calendar as a lead sponsor and keynote speaker of Tech.AD. Tech.AD has long been recognized as one of Europe’s leading technical ADAS and AD conferences. LeddarTech’s CTO Pierre Olivier will serve on the honorary jury for the 8^th Annual Tech.AD Europe Awards. These awards honor individuals and organizations who have designed exceptional solutions or products that contribute to ADAS/AD automotive development.

With a focus on environmental sensing that reimagines ADAS and AD solutions, the LeddarTech team will be participating in several capacities at this event.

Keynote presentation: July 1, 2021, 4:45 p.m. – 5:05 p.m. CET

Topic: Sensing Modalities, Sensor Fusion, and Perception for Autonomous Driving. The speaker, Pierre Olivier, Chief Technology Officer of LeddarTech, will explore the challenges and exciting opportunities facing the ADAS and AD business community.

World Café session: July 2, 2021, 1:15 p.m. – 3:35 p.m. CET

Topic: Sensor Café – Object Fusion vs. Raw Sensor Fusion – What Is the Superior Solution? Moderators: Reza Rashidi Far, PhD, and André Malz, PhD, of LeddarTech’s Strategic Product Management division.

Exhibition booth (6): July 1-2, 2021.

LeddarTech will feature solutions that solve critical sensing and perception challenges across the automotive and mobility value chain. LeddarTech will present these solutions through an innovative approach of on-site and live-streaming demonstrations of:

• Mobility and ITS sensors, including the recently released Leddar™ Sight LiDAR and the award-winning Leddar™ Pixell;
• LeddarVision™, a sensor-fusion and perception solution that delivers highly accurate 3D environmental models for L1-5 autonomy;
• Special Feature: the Westfield AutoSweep, the UK’s first fully autonomous pure electric road sweeper, featuring the Leddar Pixell.

“Our technical teams from Israel, Germany, and Italy are excited to be joining our esteemed colleagues, peers, and partners at Tech.AD. Our much-anticipated return to in-person events is especially significant as we will be showcasing our customer Westfield’s autonomous AutoSweep POD, which features the Leddar Pixell,” stated Daniel Aitken, Vice-President, Global Marketing, Communications, and Product Management at LeddarTech. “Tech.AD provides an excellent opportunity to engage with many leaders in the industry both virtually and in person, and we look forward to demonstrating our latest technology, sharing our vision, and engaging with our customers,” Mr. Aitken continued. “Tech.AD is making all efforts to implement precautions to ensure a safe and fulfilling event for all delegates, and I welcome you to visit us in person or online during the event in July,” concluded Mr. Aitken.

For more information about Tech.AD, visit autonomous-driving-berlin.com.

Prior to Tech.AD register for the Automotive IQ Webinar: June 29, 2021, 11:00 a.m. – 12:00 p.m. ET

Topic: A Clean Sweep: How Adopting Autonomous Vehicle and EV Technology Is Paving the Way to Increased Road Sweeper Efficiency and Safety While Reducing Environmental Impact. Join Pierre Olivier, CTO of LeddarTech and Julian Turner, CEO of Westfield Technology Group, for this Automotive IQ hosted event.

Register here.

About LeddarTech

LeddarTech is a leader in environmental sensing platforms for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end-to-end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments. With its LeddarVision™ sensor-fusion and perception platform and its cost-effective, scalable, and versatile LiDAR development solution for automotive-grade solid-state LiDARs based on the LeddarEngine™, LeddarTech enables Tier 1-2 automotive system integrators to develop full-stack sensing solutions for autonomy level 1 to 5. These solutions are actively deployed in autonomous shuttles, trucks, buses, delivery vehicles, smart cities/factories, and robotaxi applications. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 95 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications, and Product Management, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision, and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/2f336faf-ccca-4167-939e-c1dfcfc4c897

https://www.globenewswire.com/NewsRoom/AttachmentNg/84aebadf-f893-466e-8144-9b31e4d79c26

Westfield AutoSweep POD

LeddarTech เข้าร่วมงาน Tech.AD Europe ในฐานะผู้สนับสนุนหลักและเป็นทั้งผู้นำเสนอและผู้จัดแสดงในงานอีเว้นท์สดนี้ที่ Titanic Chaussee Berlin ประเทศเยอรมนี ในวันที่ 1-2 กรกฎาคม 2021 พบกับ LeddarTech ทั้งแบบพบกันตัวต่อตัวหรือแบบดิจิทัลโดยลงทะเบียนวันนี้ที่ autonomous-driving-berlin.com

ควิเบก ซิตี้, June 15, 2021 (GLOBE NEWSWIRE) — LeddarTech® ผู้นำระดับโลกด้านเทคโนโลยีการตรวจจับ ADAS และ AD ระดับ 1-5 รู้สึกตื่นเต้นที่จะได้กลับมาร่วมงานในสถานที่จริงอีกครั้งในฐานะผู้สนับสนุนหลักและผู้บรรยายหลักของงาน Tech.AD โดยงาน Tech.AD ได้รับการยอมรับว่าเป็นหนึ่งในการประชุม ADAS และ AD ด้านเทคนิคชั้นนำของยุโรป Pierre Olivier, CTO ของ LeddarTech จะทำหน้าที่เป็นคณะกรรมการตัดสินกิตติมศักดิ์สำหรับรางวัล Tech.AD Europe ประจำปีครั้งที่ 8 รางวัลเหล่านี้มอบเป็นเกียรติแก่บุคคลและองค์กรที่ออกแบบโซลูชันหรือผลิตภัณฑ์ที่โดดเด่นซึ่งมีส่วนช่วยในการพัฒนายานยนต์ ADAS/AD

ด้วยการมุ่งเน้นไปที่การตรวจวัดสภาพแวดล้อมที่จะกำหนดอนาคตโซลูชัน ADAS และ AD ทีม LeddarTech จะเข้าร่วมงานนี้ในหลายๆ ส่วน

การนำเสนอที่สำคัญ: 1 กรกฎาคม 2021, 16:45 น. – 17:05 น. CET

หัวข้อ: รูปแบบการตรวจจับ การรวมสัญญาณเซ็นเซอร์ และการรับรู้สำหรับการขับขี่อัตโนมัติ ผู้บรรยาย Pierre Olivier หัวหน้าเจ้าหน้าที่ฝ่ายเทคโนโลยีของ LeddarTech จะสำรวจความท้าทายและโอกาสที่น่าตื่นเต้นที่ชุมชนธุรกิจ ADAS และ AD ต้องเผชิญ

เซสชัน World Café: 2 กรกฎาคม 2021, 13:15 น. – 15:35 น. CET

หัวข้อ: Sensor Café – Object Fusion กับ Raw Sensor Fusion – อะไรคือโซลูชันที่เหนือกว่า ผู้ดำเนินการ: Reza Rashidi Far, PhD และ André Malz, PhD, แผนกการจัดการผลิตภัณฑ์เชิงกลยุทธ์ของ LeddarTech

บูธนิทรรศการ (6): 1-2 กรกฎาคม 2021

LeddarTech จะนำเสนอโซลูชันที่ช่วยแก้ปัญหาการตรวจจับและการรับรู้ที่สำคัญทั่วทั้งห่วงโซ่คุณค่ายานยนต์และการเคลื่อนที่ LeddarTech จะนำเสนอโซลูชันเหล่านี้ผ่านแนวทางที่ล้ำสมัยของการสาธิตในงานและการสตรีมสดของ:

• เซ็นเซอร์การเคลื่อนที่และ ITS รวมถึง Leddar™ Sight LiDAR ที่เปิดตัวเมื่อไม่นานมานี้และ Leddar™ Pixell ที่ได้รับรางวัล
• LeddarVision™ โซลูชันการรวมสัญญาณและการรับรู้ที่มอบแบบจำลองสภาพแวดล้อม 3 มิติที่แม่นยำสูงสำหรับยานยนต์อัตโนมัติระดับ 1-5
• หัวข้อเด่น: Westfield AutoSweep รถกวาดถนนไฟฟ้าแบบไร้คนขับอัตโนมัติเต็มรูปแบบคันแรกของสหราชอาณาจักร ที่ใช้ Leddar Pixell

“ทีมเทคนิคของเราจากอิสราเอล เยอรมนี และอิตาลีรู้สึกตื่นเต้นที่จะได้ร่วมงานกับเพื่อนร่วมงาน เพื่อนๆ และพันธมิตรที่งาน Tech.AD การกลับมาเข้าร่วมกิจกรรมแบบพบปะตัวต่อตัวที่เราตั้งตารอนั้นมีความสำคัญอย่างยิ่ง เนื่องจากเราจะจัดแสดง AutoSweep POD อัตโนมัติของ Westfield ซึ่งใช้ Leddar Pixell ต่อลูกค้าของเรา” Daniel Aitken รองประธานฝ่ายการตลาด การสื่อสาร และการจัดการผลิตภัณฑ์ระดับโลกของ LeddarTech กล่าว “Tech.AD มอบโอกาสที่ยอดเยี่ยมในการมีส่วนร่วมกับผู้นำจำนวนมากในอุตสาหกรรม ทั้งแบบเสมือนจริงและแบบตัวต่อตัว และเราหวังว่าจะได้สาธิตเทคโนโลยีล่าสุด แบ่งปันวิสัยทัศน์ และมีส่วนร่วมกับลูกค้าของเรา” Mr. Aitken ได้กล่าวต่อ “Tech.AD พยายามอย่างเต็มที่ในการนำมาตรการป้องกันมาใช้เพื่อให้แน่ใจถึงความปลอดภัยและความพึงพอใจของตัวแทน และเราเชิญให้คุณมาเยี่ยมเราด้วยตัวคุณเองหรือแบบออนไลน์ระหว่างการจัดงานในเดือนกรกฎาคม” Mr. Aitken กล่าวสรุป

สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Tech.AD โปรดไปที่ autonomous-driving-berlin.com

ลงทะเบียนเข้าร่วมการสัมมนาออนไลน์ Automotive IQ ก่อนงาน Tech.AD: 29 มิถุนายน 2021, 11:00 น. – 12:00 น. ET

หัวข้อ: A Clean Sweep: การนำเทคโนโลยียานยนต์ไร้คนขับและเทคโนโลยี EV มาใช้เป็นการปูทางไปสู่การเพิ่มประสิทธิภาพและความปลอดภัยของรถกวาดถนนพร้อมทั้งลดผลกระทบต่อสิ่งแวดล้อมได้อย่างไร พบกับ Pierre Olivier, CTO ของ LeddarTech และ Julian Turner, CEO ของ Westfield Technology Group สำหรับงาน Automotive IQ ที่จัดขึ้นมานี้

ลงทะเบียนที่นี่

เกี่ยวกับ LeddarTech

LeddarTech เป็นผู้นำในด้านแพลตฟอร์มการตรวจจับสภาพแวดล้อมสำหรับยานยนต์อัตโนมัติและระบบช่วยเหลือผู้ขับขี่ขั้นสูง LeddarTech ก่อตั้งในปี 2007 โดยได้พัฒนาเป็นบริษัทการตรวจจับสภาพแวดล้อมแบบครบวงจรโดยให้ลูกค้าสามารถแก้ไขปัญหาการตรวจจับและการรับรู้ที่สำคัญได้ทั่วทั้งห่วงโซ่คุณค่าของตลาดยานยนต์และการเคลื่อนที่ ด้วยแพลตฟอร์มการรวมสัญญาณเซ็นเซอร์และการรับรู้ของ LeddarVision™ และโซลูชันการพัฒนา LiDAR ที่คุ้มค่า ปรับขนาดได้ และอเนกประสงค์ LiDAR แบบโซลิดสเตตระดับยานยนต์ที่ใช้งาน LeddarEngine™ ทำให้ LeddarTech ช่วยให้ผู้วางระบบยานยนต์ระดับ Tier 1-2 พัฒนาโซลูชันการตรวจจับแบบครอบคลุมทั้งหมดสำหรับยานยนต์อัตโนมัติระดับ 1 ถึง 5 โซลูชันนี้ได้รับการปรับใช้ในการใช้งานรถรับส่งขับขี่อัตโนมัติ รถบรรทุก รถโดยสารประจำทาง รถส่งสินค้า เมือง/โรงงานอัจฉริยะ และแท็กซี่ไร้คนขับ บริษัทเป็นผู้รับผิดชอบในการคิดค้นนวัตกรรมใหม่ๆ ในแอปพลิเคชันตรวจจับยานยนต์และการเคลื่อนที่ระยะไกลที่ทันสมัยด้วยเทคโนโลยีที่จดสิทธิบัตรมากกว่า 95 รายการ (จดสิทธิบัตรแล้วหรือรอดำเนินการ) ที่ช่วยเสริมขีดความสามารถ ADAS และการขับขี่แบบอัตโนมัติ

สามารถดูข้อมูลเพิ่มเติมเกี่ยวกับ LeddarTech ได้ที่ www.leddartech.com และบน LinkedIn, Twitter, Facebook และ YouTube

ติดต่อ:
Daniel Aitken รองประธานฝ่ายการตลาด การสื่อสารและการจัดการผลิตภัณฑ์ระดับโลก LeddarTech Inc.
โทร: + 1-418-653-9000 ต่อ 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision และโลโก้ที่เกี่ยวข้องเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนของ LeddarTech Inc. และบริษัทในเครือ แบรนด์ ชื่อผลิตภัณฑ์ และเครื่องหมายต่างๆ ทั้งหมดเป็นหรืออาจเป็นเครื่องหมายการค้าที่ใช้เพื่อระบุถึงผลิตภัณฑ์หรือบริการต่างๆ ของเจ้าของที่เกี่ยวข้อง

สามารถรับชมรูปภาพประกอบของการแถลงนี้ได้ที่:

https://www.globenewswire.com/NewsRoom/AttachmentNg/2f336faf-ccca-4167-939e-c1dfcfc4c897/th

https://www.globenewswire.com/NewsRoom/AttachmentNg/84aebadf-f893-466e-8144-9b31e4d79c26/th

London, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) — SNOMED International is pleased to announce the launch of a new report that details the value each of its many stakeholder groups can experience by implementing SNOMED CT, the most comprehensive global language for health terms. This report builds on the work captured in a series of videos completed in 2020 in which a New Zealand health board highlights the advances it has made in realizing its vision of a connected, integrated system by using SNOMED CT.

The report, titled SNOMED CT: Articulating Stakeholder Value, was developed over the past year as part of our efforts to meet our 2020-2025 Strategy commitments and to realize our vision of better health and improved patient outcomes worldwide.

It identifies where and how SNOMED CT is used, providing an end-to-end perspective of the entire universe of SNOMED CT users, including Members, policy makers, care providers, patients and citizens, researchers and knowledge producers, implementers, vendors and collaboration partners, and expands and extends our existing value propositions to each of those groups. It also lays out the pathway to realizing the full value of SNOMED CT when embedded in a clinical information system, a health data and analytics platform or an interoperability solution.

“There has been enormous evolution in the SNOMED CT product and community since the organization came into being,” states Don Sweete, CEO of SNOMED International. “As the organization and our community have evolved, so, too, has the value that the product and its resources offer healthcare systems and stakeholders worldwide.” Don also noted, “As a core clinical reference terminology that is unchallenged in terms of its clinical breadth and depth, our renewed value propositions mirror the evolution of our stakeholders in their past, present and future use of SNOMED CT.”

Based on the Delone and McLean IS Success Framework as the theoretical underpinning for the development of these segmented value propositions, the report demonstrates the role of SNOMED CT as a critical component of the entire ecosystem of clinical terminologies and the importance of collaboration among the sponsors of those terminologies.

It also provides government decision-makers with a clear understanding of how their investments in SNOMED CT translate into positive outcomes for the health of their nation’s citizens.

Highlights of the benefits by stakeholder groups

• Policymakers are more informed when making policy and management decisions, accelerating data-driven analytics and decision-making processes
• Members can ensure that high-quality clinical information is available to stakeholders within their nations
• Collaboration Partners contribute their best-in-class clinical knowledge to SNOMED CT to ensure its clinical integrity and create the one language of health
• Researchers and Knowledge Producers can accelerate data, information, evidence and knowledge creation, supporting a wide range of analytics and research to benefit the decision-making of policymakers and healthcare stakeholders
• Implementers can collect data once and reuse it for a diverse range of clinical, management and research purposes to support a broad range of health stakeholders
• Vendors can open up markets globally and expand market share by enhancing the information quality of their products, using a global standard used in over 80 countries
• Care Providers can improve patient outcomes by being knowledgeable about their patient’s health and options for care, achieving a more informed and collaborative relationship when making critical care decisions
• Patients/Citizens can control their own health information and be knowledgeable about their health and self-care options

Over the coming months, SNOMED International will build on this work with the release of an in-depth SNOMED CT Case for Investment, supported by economic benefits modeling and data-driven exemplar case studies of SNOMED CT use.

To read the report, Articulating Stakeholder Value, visit snomed.org/value.

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

Media Inquiries

Kelly Kuru

Chief Communications Officer

comms@snomed.org

Attachments

• SCT-Value General 1-1200x1200px-FacebookSquarePost
• SCT-Value General 3-1200x1200px-FacebookSquarePost

Kelly Kuru
SNOMED International
comms@snomed.org

ATLANTA, June 14, 2021 (GLOBE NEWSWIRE) — First Advantage Corporation, a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital, today announced the launch of the initial public offering of 21,250,000 shares of its common stock, of which 17,750,000 shares of common stock will be sold by First Advantage and 3,500,000 shares of common stock will be sold by certain existing stockholders of First Advantage. First Advantage and the selling stockholders expect to grant the underwriters in the offering a 30-day option to purchase up to an additional 3,187,500 shares of common stock, of which, up to 2,662,500 shares of common stock would be sold by First Advantage and up to 525,000 shares of common stock would be sold by certain existing stockholders of First Advantage. The estimated initial public offering price is between $13.00 and $15.00 per share. First Advantage has applied to list its shares on the Nasdaq Global Select Market under the symbol “FA”.

Barclays, BofA Securities and J.P. Morgan will act as lead bookrunners for the proposed offering. Citigroup, Evercore ISI, Jefferies, RBC Capital Markets, Stifel and HSBC will act as bookrunners, and Citizens Capital Markets, KKR Capital Markets LLC, MUFG, Loop Capital Markets, R. Seelaus & Co., LLC, Ramirez & Co., Inc. and Roberts & Ryan will act as co-managers for the proposed offering.

A registration statement on Form S-1 relating to the proposed offering has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering can be obtained from: Barclays Capital Inc., Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 888-603-5847, or by email at Barclaysprospectus@broadridge.com; BofA Securities, Attn: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina, 28255-0001, by email at dg.prospectus_requests@bofa.com; or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866-803-9204 or by email at prospectuseq_fi@jpmorganchase.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include any statements regarding the commencement of trading of First Advantage’s common stock on the Nasdaq Global Select Market. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under “Risk Factors” under First Advantage’s registration statement relating to the offering. Except as required by law, First Advantage has no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

About First Advantage

First Advantage is a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital. The company delivers innovative solutions and insights that help customers manage risk and hire the best talent. Enabled by its proprietary technology platform, First Advantage’s products and solutions help companies protect their brands and provide safe environments for their customers and their most important resources: employees, contractors, contingent workers, tenants and drivers. Headquartered in Atlanta, Georgia, First Advantage has offices in North America, Europe, Asia and the Middle East.

Media Contact:

Elisabeth Warrick
First Advantage
employment.solutions@fadv.com
(888) 314-9761

Jeanne Achille
The Devon Group
firstadvantage@devonpr.com
+1-732-706-0123, ext. 700

LONDON, June 14, 2021 (GLOBE NEWSWIRE) — London and Hong Kong-based risk management consultancy A2 Global Risk published a new report assessing the investment risks associated with port infrastructure expansion in Sub-Saharan Africa, against the backdrop of global geopolitical competition. The COVID-19 pandemic and associated restrictions on travel and operations caused unprecedented disruption to international trade and highlighted the risks linked with ageing port infrastructure and regional bottlenecks.

Cognisant of such risks, African governments are actively seeking to expand their infrastructure and trade provisions to reduce non-tariff barriers, as part of their efforts to modernise their trade infrastructure, such as airports, seaports, roads, and internet access. International actors active in this space are ramping up their competition for market access amid mounting trade and geopolitical tensions globally.

In Africa, traditional global powers such as France and the European Union on one hand, and China on the other, have for years competed over lucrative port expansion and management contracts. But both Western and Chinese companies have been accused of abuses and neo-colonialism. A growing number of Middle Eastern countries, led by the United Arab Emirates as well as Turkey, is now providing a third alternative.

While this growing competition offers African countries new alternatives to choose from, which may in turn foster local agency, it also raises questions about responsible corporate actors and signals emerging political risks to companies with an established presence.

“Gulf countries, particularly Saudi Arabia and the UAE, have markedly increased their presence on the continent, particularly in the Horn of Africa, over the past decade,” says Senior Analyst for Sub-Saharan Africa Olivier Milland. “To a large extent this forms part of their strategic development plans to diversify economies and secure future food supplies. Meanwhile, efforts at home to attract foreign capital or entice companies to establish offices in the region means that corporate standards there need to be elevated to the same level as those in advanced economies, placing a greater compliance burden on Gulf-based companies if they are to maintain a competitive advantage.”

About A2 Global RIsk
A2 Global Risk is a political and security risk management consultancy headquartered in Hong Kong with offices throughout Asia-Pacific as well as London and Washington DC. We provide subscription-based Information Services platform and bespoke security risk management services across the globe to help companies understand their political environments and mitigate risk accordingly. For more information visit www.a2globalrisk.com.

CONTACTS:
Carolyn Taylor
Senior Editor
Tel: +44 203 102 4053
Email: ctaylor@a2globalrisk.com

une 14, 2021

• Philips is initiating a voluntary recall notification* to ensure patient safety in consultation with regulatory agencies
• Corrective actions include the deployment of updated instructions for use and a repair and replacement program for affected devices
• Philips aims to address all affected devices within the scope of this correction as expeditiously as possible

Amsterdam, the Netherlands – Following the company update on April 26, 2021, Royal Philips (NYSE: PHG; AEX: PHIA) today provides an update on the recall notification* for specific Philips Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP), and mechanical ventilator devices to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam component in these devices. The majority of the affected devices within the advised 5-year service life are in the first-generation DreamStation product family.

To date, Philips has produced millions of Bi-Level PAP, CPAP and mechanical ventilator devices using the PE-PUR sound abatement foam. Despite a low complaint rate (0.03% in 2020), Philips determined based on testing that there are possible risks to users related to this type of foam. The risks include that the PE-PUR foam may degrade into particles which may enter the device’s air pathway and be ingested or inhaled by the user, and the foam may off-gas certain chemicals. The foam degradation may be exacerbated by use of unapproved cleaning methods, such as ozone,** and high heat and high humidity environments may also contribute to foam degradation.

Therefore, Philips has decided to voluntarily issue a recall notification* to inform patients and customers of potential impacts on patient health and clinical use related to this issue, as well as instructions on actions to be taken.

“We deeply regret any concern and inconvenience that patients using the affected devices will experience because of the proactive measures we are announcing today to ensure patient safety,” said Frans van Houten, CEO of Royal Philips. “In consultation with the relevant regulatory agencies and in close collaboration with our customers and partners, we are working hard towards a resolution, which includes the deployment of the updated instructions for use and a comprehensive repair and replacement program for the affected devices. Patient safety is at the heart of everything we do at Philips.”

Recall notification* advise for patients and customers
Based on the latest analysis of potential health risks and out of an abundance of caution, the recall notification* advises patients and customers to take the following actions:

• For patients using affected BiLevel PAP and CPAP devices: Discontinue use of your device and work with your physician or Durable Medical Equipment (DME) provider to determine the most appropriate options for continued treatment. To continue use of your device due to lack of alternatives, consult with your physician to determine if the benefit of continuing therapy with your device outweighs the risks identified in the recall notification.*
• For patients using affected life-sustaining mechanical ventilator devices: Do not stop or alter your prescribed therapy until you have talked to your physician. Philips recognizes that alternate ventilator options for therapy may not exist or may be severely limited for patients who require a ventilator for life-sustaining therapy, or in cases where therapy disruption is unacceptable. In these situations, and at the discretion of the treating clinical team, the benefit of continued usage of these ventilator devices may outweigh the risks identified in the recall notification.*

Possible health risks
The company continues to monitor reports of potential safety issues as required by medical device regulations and laws in the markets in which it operates. To date, there have been no reports of death as a result of these issues. Philips has received reports of possible patient impact due to foam degradation. The potential risks of particulate exposure include headache, irritation, inflammation, respiratory issues, and possible toxic and carcinogenic effects. The potential risks of chemical exposure due to off-gassing include headache, irritation, hypersensitivity, nausea/vomiting, and possible toxic and carcinogenic effects. Philips has received no reports regarding patient impact related to chemical emissions.

Repair and replacement program
Philips is providing the relevant regulatory agencies with required information related to the launch and implementation of the projected correction. The company will replace the current sound abatement foam with a new material and has already begun the preparations, which include obtaining the relevant regulatory clearances. Philips aims to address all affected devices in scope of this correction as expeditiously as possible.

As part of the program, the first-generation DreamStation product families will be modified with a different sound abatement foam and shipped upon receipt of the required regulatory clearances. Philips’ recently launched next-generation CPAP platform, DreamStation 2, is not affected by the issue. To support the program, Philips is increasing the production of its DreamStation 2 CPAP devices, that are available in the US and selected countries in Europe.

Financials
In terms of the financial impact, Philips anticipates that the expected revenue headwinds in the Sleep & Respiratory Care business in 2021 will be compensated by the strength of the company’s other businesses. Therefore, the full year comparable sales growth and Adjusted EBITA margin guidance provided on April 26, 2021 remains unchanged.

The updated instructions for use of the affected devices have resulted in adjustments to and acceleration of the repair and replacement program, as well as intensified communication with customers and patients. This had led to an increase of EUR 250 million in the expected costs of the corrective actions on the installed base, in addition to the provision that the company recorded in the first quarter of 2021.

Additional information
For more information on the recall notification,* as well as instructions for customers, users and physicians, affected parties may contact their local Philips representative or visit www.philips.com/SRC-update.

*     This is a recall notification for the US only, and a field safety notice for the rest of the world
**   Potential Risks Associated With The Use of Ozone and Ultraviolet (UV) Light Products for Cleaning CPAP Machines and Accessories: FDA Safety Communication.

For media and investor questions, please contact:

Steve Klink
Philips Global Press Office
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Leandro Mazzoni
Philips Investor Relations
Tel.: +31 20 59 77222
E-mail: leandro.mazzoni@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.